Managing CNS Progression in Metastatic Triple-Negative Breast Cancer

The chapter delves into a specific case of a 59-year-old woman with metastatic triple-negative breast cancer experiencing CNS progression. Discussions revolve around the challenges of balancing systemic treatment and local therapy, including the complexity of addressing impending visceral crises. The speakers also analyze the use of TDXD and antibody drug conjugates in managing brain metastases, along with ongoing trials like ASCENT 3 and SENTO3/SENTO4 in the treatment of metastatic triple-negative breast cancer.